Sema4C/PlexinB2 signaling controls breast cancer cell growth, hormonal dependence and tumorigenic potential
Sreeharsha Gurrapu1, Emanuela Pupo2, Giulia Franzolin1,3
1Cancer Cell Biology Laboratory, Candiolo Cancer Institute-FPO, IRCCS, Candiolo, Italy.
Abstract:
Semaphorin 4C (Sema4C) expression in human breast cancers correlates with poor disease outcome. Surprisingly, upon knock-down of Sema4C or its receptor PlexinB2 in diverse mammary carcinoma cells (but not their normal counterparts), we observed dramatic growth inhibition associated with impairment of G2/M phase transition, cytokinesis defects and the onset of cell senescence. Mechanistically, we demonstrated a Sema4C/PlexinB2/LARG-dependent signaling cascade that is required to maintain critical RhoA-GTP levels in cancer cells. Interestingly, we also found that Sema4C upregulation in luminal-type breast cancer cells drives a dramatic phenotypic change, with disassembly of polarity complexes, mitotic spindle misorientation, cell-cell dissociation and increased migration and invasiveness. We found that this signaling cascade is dependent on the PlexinB2 effectors ErbB2 and RhoA-dependent kinases. Moreover, Sema4C-overexpressing luminal breast cancer cells upregulated the transcription factors Snail, Slug and SOX-2, and formed estrogen-independent metastatic tumors in mice. In sum, our data indicate that Sema4C/PlexinB2 signaling is essential for the growth of breast carcinoma cells, featuring a novel potential therapeutic target. In addition, elevated Sema4C expression enables indolent luminal-type tumors to become resistant to estrogen deprivation, invasive and metastatic in vivo, which could account for its association with a subset of human breast cancers with poor prognosis.
Insights
Semaphorin 4C (Sema4C) signaling drives breast cancer growth and metastasis. Inhibiting Sema4C or its receptor PlexinB2 halts tumor cell proliferation and invasiveness, revealing a potential therapeutic target.
Area of Science:
- Oncology
- Cell Biology
- Molecular Signaling
Background:
- Semaphorin 4C (Sema4C) expression is linked to poor outcomes in human breast cancers.
- The role of Sema4C in breast cancer progression, particularly in luminal-type cancers, requires further elucidation.
Purpose of the Study:
- To investigate the functional role of Semaphorin 4C (Sema4C) and its receptor PlexinB2 in breast cancer cell growth, phenotype, and metastasis.
- To identify the underlying molecular mechanisms of Sema4C/PlexinB2 signaling in breast carcinoma.
Main Methods:
- Knock-down experiments of Sema4C and PlexinB2 in mammary carcinoma cell lines.
- Analysis of cell cycle progression, cytokinesis, and senescence.
- Investigation of RhoA-GTP levels and downstream signaling pathways.
- Assessment of phenotypic changes including cell polarity, migration, and invasiveness.
- In vivo studies using mouse models of estrogen-independent metastatic tumors.
Main Results:
- Sema4C/PlexinB2 signaling is crucial for maintaining RhoA-GTP levels, essential for cancer cell proliferation.
- Inhibition of Sema4C/PlexinB2 leads to growth arrest, cell cycle defects, and senescence in carcinoma cells.
- Sema4C upregulation induces phenotypic changes promoting invasiveness and metastasis, including altered cell polarity and increased transcription factors like Snail, Slug, and SOX-2.
- Sema4C-overexpressing cells form estrogen-independent metastatic tumors in vivo.
- The signaling cascade involves ErbB2 and RhoA-dependent kinases.
Conclusions:
- Sema4C/PlexinB2 signaling is a critical driver of breast carcinoma cell growth and represents a novel therapeutic target.
- Elevated Sema4C expression promotes the transition of indolent luminal breast cancers to an aggressive, metastatic phenotype, potentially explaining its association with poor prognosis.
Related Concept Videos
Contact-dependent Signaling
Gap Junctions
In animal cells, gap junctions are formed...
Types of Hormones
Plant Hormones
Cell-surface Signaling
Calmodulin-dependent Signaling
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
Hormonal Control of the Ovarian Cycle
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...


